The strategic pivot to immunology with non-dilutive capital is a strong catalyst. Monitor Phase 2 initiation in IgG4-RD in Q2 2027 and any data from Innovent's SjD Phase 2 in China. The Utebzi royalty stream provides a downside floor, but clinical development risk remains high. Watch for potential partnership expansion or additional financing needs.
Price Chart
Executive Summary
Spero Therapeutics in-licensed SP001 (IBI355), a Phase 2-ready anti-CD40L antibody, from Innovent Biologics for $35M upfront and up to ~$1.1B in milestones + tiered royalties, marking a strategic pivot to immunology. Concurrently, it secured $105M non-recourse, non-dilutive royalty financing backed by future Utebzi (tebipenem pivoxil) milestones and royalties from GSK, extending cash runway into 2H 2029. The company plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027.
Key Financial Metrics
Key Facts
- Exclusive license for SP001 (IBI355) from Innovent, covering global rights ex-Greater China
- $35M upfront payment to Innovent; up to $1.05B in development, regulatory, and commercial milestones
- $105M non-recourse financing from HCRx (KKR), backed by a portion of GSK's Utebzi milestone/royalty payments
- Cash runway extended into second half of 2029
- Phase 2 trial in IgG4-RD expected to start Q2 2027; Innovent plans Phase 2 in Sjögren's disease in China by early 2027
- SP001 is a third-generation Fc-silent anti-CD40L mAb with Phase 1b safety/efficacy data in Sjögren's disease
Financial Impact
$35M upfront payment to Innovent + up to $1.1B in contingent milestones; $105M non-dilutive financing provides immediate capital; no dilution to common equity
Risk Factors
- Clinical development risk for SP001 in IgG4-RD and other indications
- Milestone payments create a significant future financial obligation to Innovent
- Competition from other CD40L-targeting agents and B-cell therapies
- Dependence on GSK's commercialization of Utebzi for royalty stream to service the HCRx financing
- No approved products in immunology pipeline; execution risk in new therapeutic area
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-302473 |
| Document: d320658dex993.htm | 0001193125-26-302473 |
| Document: d320658dex991.htm | 0001193125-26-302473 |
| Document: d320658dex992.htm | 0001193125-26-302473 |
| Document: 0001193125-26-302473-index-headers.html | 0001193125-26-302473 |
| Document: 0001193125-26-302473-index.html | 0001193125-26-302473 |
| Document: 0001193125-26-302473.txt | 0001193125-26-302473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access